Journal of Clinical Oncology, Vol 18, Issue 7
(April), 2000: 1539-1549
© 2000 American Society for Clinical Oncology
Longitudinal Study of Adaptation to the Stress of Bone Marrow Transplantation
By Betsy L. Fife,
Gertrude A. Huster,
Kenneth G. Cornetta,
Victoria N. Kennedy,
Luke P. Akard,
E. Randolph Broun
From the Indiana University School of Nursing, Indiana University Cancer Center; Indiana University School of Medicine; Walther Cancer Institute; and Methodist Hospital of Indiana, Indianapolis, IN.
Address reprint requests to Betsy Fife, PhD, Indiana University Medical Center, 1111 Middle Dr, No 340, Indianapolis, IN 46202; email iuoq700{at}iupui.edu
PURPOSE: This prospective longitudinal study of adaptation to bone marrow transplantation (BMT) addressed three questions: (1) When during BMT do individuals experience the greatest distress? (2) What factors are associated with this distress? (3) Are there variables that could be potential clinical indicators of persons in greatest need of preventive intervention?
PATIENTS AND METHODS: One hundred one participants undergoing either an autologous or allogeneic BMT completed questionnaires before hospitalization, before bone marrow infusion, 7 days and 14 days after transplantation, and then 1 month, 3 months, and 12 months after hospitalization. Adaptation was indicated by the degree of emotional distress. Independent variables were personal control, social support from specific sources, cognitive response, self-perception, and coping strategies, controlling for symptomatology.
RESULTS: The greatest emotional distress occurred after admission to the hospital and before the bone marrow infusion. Anxiety and depression decreased 1 week after the transplant, although symptomatology increased during this time. The periods of least emotional distress were 3 months and 1 year after transplantation. Factors that accounted for the greatest variance in emotional distress/adaptation were the degree of emotional distress at baseline, personal control, cognitive response, and symptomatology.
CONCLUSION: According to this longitudinal study, which includes pretransplant data, data from in-hospital transplantation, and posttransplant data, (1) psychosocial vulnerability of these BMT recipients was greatest during hospitalization before the transplant, (2) perceived personal control may be a potential indicator of vulnerability to secondary psychosocial morbidity, and (3) the demonstrated significance of psychosocial well-being before BMT indicates the importance of obtaining prospective data for both research and clinical purposes.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. M. Prieto, J. Atala, J. Blanch, E. Carreras, M. Rovira, E. Cirera, A. Espinal, and C. Gasto
Role of Depression As a Predictor of Mortality Among Cancer Patients After Stem-Cell Transplantation
J. Clin. Oncol.,
September 1, 2005;
23(25):
6063 - 6071.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Chang, E. J. Orav, T. K. McNamara, M.-Y. Tong, and J. H. Antin
Psychosocial Function After Hematopoietic Stem Cell Transplantation
Psychosomatics,
February 1, 2005;
46(1):
34 - 40.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. C. Trask
Assessment of Depression in Cancer Patients
J Natl Cancer Inst Monographs,
July 1, 2004;
2004(32):
80 - 92.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. Syrjala, S. L. Langer, J. R. Abrams, B. Storer, J. E. Sanders, M. E. D. Flowers, and P. J. Martin
Recovery and Long-term Function After Hematopoietic Cell Transplantation for Leukemia or Lymphoma
JAMA,
May 19, 2004;
291(19):
2335 - 2343.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Brandberg, H. Michelson, B. Nilsson, C. Bolund, B. Erikstein, P. Hietanen, S. Kaasa, J. Nilsson, T. Wiklund, N. Wilking, et al.
Quality of Life in Women With Breast Cancer During the First Year After Random Assignment to Adjuvant Treatment With Marrow-Supported High-Dose Chemotherapy With Cyclophosphamide, Thiotepa, and Carboplatin or Tailored Therapy With Fluorouracil, Epirubicin, and Cyclophosphamide: Scandinavian Breast Group Study 9401
J. Clin. Oncol.,
October 1, 2003;
21(19):
3659 - 3664.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Prieto, J. Blanch, J. Atala, E. Carreras, M. Rovira, E. Cirera, and C. Gasto
Psychiatric Morbidity and Impact on Hospital Length of Stay Among Hematologic Cancer Patients Receiving Stem-Cell Transplantation
J. Clin. Oncol.,
April 1, 2002;
20(7):
1907 - 1917.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|